The Blog

The first major renewal cycle for REACH authorisations covering octylphenol ethoxylates (OPnEO) and nonylphenol ethoxylates (NPnEO) is now underway. Since their inclusion in Annex XIV, these substances have become among the most frequently authorised substance groups under REACH, particularly in In Vitro Diagnostics (IVDs), medical technologies, pharmaceutical manufacturing, biotechnology applications and other life-science sectors. Recent reporting indicates that around 75 authorisation decisions have been adopted, with a significant number of review periods now approaching expiry.

For many companies, the immediate response may be to start planning a review report. However, as the regulatory landscape evolves and individual operations change, it is worth asking a broader question:

Is a review report always the appropriate next step?

The Next Phase for Entries 42 and 43

Entry 42 covers 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated (OPnEO, including Triton X-100-related substances), while Entry 43 covers 4-nonylphenol, branched and linear, ethoxylated (NPnEO). Both were included in Annex XIV due to their endocrine-disrupting properties for the environment, with a latest application date of 4 July 2019 and a sunset date of 4 January 2021.

Following their inclusion, a large number of healthcare and life-science companies obtained authorisations to secure continued use in critical applications. Several authorisations have already reached the end of their review periods, while a further 25-30 review periods are expected to expire between 2027 and 2031.

Given that review reports must be submitted well in advance of review period expiry, the strategic decisions associated with these authorisations are no longer a future consideration. For many businesses, that process has already begun. 

Why Healthcare and Life-Science Applications Present Unique Challenges

A substantial proportion of OPnEO and NPnEO authorisations relate to highly regulated healthcare and life-science applications.

Within the IVD sector, these substances are often used as surfactants that contribute to critical assay performance characteristics such as sensitivity, specificity, stability and overall reliability. Replacing these substances is often considerably more complex than a simple reformulation exercise, as changes may require extensive development work, validation and regulatory approvals.

Similar challenges arise in biopharmaceutical manufacturing, vaccine production, chromatography applications and advanced therapies, where process changes may have significant technical, quality and regulatory implications.

As a result, many organisations are now facing important strategic questions:

• Has substitution progressed sufficiently since the original authorisation?
• Are the assumptions used in the original application still valid?
• Does the existing authorisation still reflect current operations?
• What is the most proportionate compliance approach going forward?

Looking Beyond the Review Report

Review reports remain an essential requirement for many continued uses. However, focusing solely on preparation of the review dossier may overlook important strategic considerations.

Many OPnEO and NPnEO authorisations were prepared several years ago. Since then:

• manufacturing processes may have changed;
• annual volumes may have decreased;
• substitution programmes may have advanced;
• product portfolios may have evolved; and
• the practical use profile may differ significantly from the original application.

For that reason, companies approaching review deadlines may benefit from first conducting a structured assessment of their current situation.

Questions worth considering include:

• Does the current use still require authorisation?
• Does the current use profile match the original authorised use?
• Have operational changes altered the regulatory assessment?
• Could different activities within the organisation require different regulatory approaches?
• Are there potential exemptions that warrant evaluation?

These questions can be particularly relevant where quantities are low, environmental releases are tightly controlled, and activities take place in highly regulated professional settings.

A Changing Regulatory Context

The upcoming review cycle is taking place against a backdrop of wider discussions concerning the future implementation of REACH authorisation in highly regulated sectors, particularly healthcare and life-science applications. Recent regulatory commentary has highlighted questions around substitution timelines, the interaction between REACH and sector-specific legislation, and the practical experience gained since the first OPnEO and NPnEO authorisations were granted.

While the future direction of regulatory developments remains uncertain, organisations approaching review periods should ensure that their compliance strategy reflects both current operational realities and the evolving regulatory landscape.

Preparing for the Next Renewal Cycle

Organisations approaching review deadlines should consider two complementary workstreams.

1. Review Report Preparation

For uses that will continue under authorisation, early preparation remains essential and may include:

• review strategy development;
• updates to the Analysis of Alternatives;
• substitution planning;
• socio-economic assessment;
• review period justification; and
• support throughout RAC, SEAC and Commission decision-making processes.

2. Strategic Regulatory Assessment

Before committing to a review report, organisations may also wish to reassess their current use profile and wider regulatory position.

This may include consideration of:

• changes since the original authorisation;
• ongoing substitution activities;
• applicability of potential exemptions;
• future regulatory developments; and
• long-term compliance strategy.

In some cases, this assessment may simply confirm that a review report remains the most appropriate path forward. In others, it may help identify additional options that merit further analysis before substantial resources are committed.

Looking Ahead

The OPnEO and NPnEO renewal cycle represents more than the next round of REACH authorisation reviews.

For many organisations, it provides the first opportunity to evaluate how their operations, supply chains, products and regulatory obligations have evolved since the original authorisation applications were prepared.

Companies that begin this exercise early will be best positioned to make informed decisions, whether that ultimately leads to a review report, continued substitution efforts, an updated regulatory strategy or evaluation of other compliance pathways.

As review periods continue to approach across the diagnostics, medical technology, biopharmaceutical and broader life-science sectors, now is the time to start that assessment.